The Department of Justice's antitrust review of CVS Health's $69 billion bid for Aetna is taking longer due to divestitures needed to ensure competition is not impeded, a source familiar with the matter told Reuters.
To ease anticompetitive concerns, federal regulators will require CVS and Aetna to divest some of their Medicare Part D assets, the people familiar with the matter told The Wall Street Journal in early September. A potential bidder for the Part D assets is WellCare Health Plans, but conversations between CVS and Aetna are still ongoing, the sources said.
Sources told Reuters the Justice Department's review may conclude soon, though it is not clear whether approval will come in September.